We are live on
!
Find out more
XT
XTX Topco Portfolio holdings
AUM
$5.75B
1-Year Est. Return
30.56%
This Fund
S&P 500
This Quarter
Est. Return
+0.17%
1 Year Est. Return
+30.56%
3 Year Est. Return
+70.38%
5 Year Est. Return
+43.83%
10 Year Est. Return
–
AUM
$3.81B
AUM Growth
+$1.88B
(+98%)
Cap. Flow
+$1.94B
Cap. Flow
% of AUM
50.99%
Top 10 Holdings %
Top 10 Hldgs %
5.52%
Holding
3,983
New
1,493
Increased
1,108
Reduced
652
Closed
727
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$25.6M |
| 2 |
JPMorgan Chase
JPM
|
+$21.7M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$19.7M |
| 4 |
Kroger
KR
|
+$17.9M |
| 5 |
T-Mobile US
TMUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$11.3M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$8.42M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$8.34M |
| 4 |
Cisco
CSCO
|
+$8.02M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$8.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.84% |
| 2 | Technology | 16.54% |
| 3 | Industrials | 11.45% |
| 4 | Healthcare | 11.32% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2901
BARK
BARK
$78.4M
| $37.7K | ﹤0.01% |
+3,127
| New | +$46.4K |
|
2902
Soligenix
SNGX
$5.36M
| $37.4K | ﹤0.01% |
+27,926
| New | +$41.5K |
|
2903
Atea Pharmaceuticals
AVIR
$361M
| $37.3K | ﹤0.01% |
10,439
-11,836
| -53% | -$37.6K |
|
2904
Globus Maritime Ltd
GLBS
$60.9M
| $37.1K | ﹤0.01% |
21,209
+8,327
| +65% | +$11.2K |
|
|
FORA
2905
DELISTED
Forian
FORA
| $37.1K | ﹤0.01% |
+17,489
| New | +$38.2K |
|
2906
Zedge
ZDGE
$38.4M
| $37K | ﹤0.01% |
11,281
-4,630
| -29% | -$13.4K |
|
2907
Solitario Resources
XPL
$67.9M
| $36.9K | ﹤0.01% |
53,018
+34,415
| +185% | +$22.7K |
|
|
MF
2908
MindForge Inc. Class A Ordinary Shares
MF
$12.1M
| $36.5K | ﹤0.01% |
+738
| New | +$38K |
|
|
OKYO
2909
OKYO Pharma
OKYO
$86.1M
| $36.5K | ﹤0.01% |
+17,612
| New | +$38.2K |
|
2910
China SXT Pharmaceuticals
SXTC
$2.2M
| $36.4K | ﹤0.01% |
+152
| New | +$32.9K |
|
|
ALLR
2911
Allarity Therapeutics
ALLR
$18.8M
| $36.3K | ﹤0.01% |
+33,644
| New | +$42.9K |
|
|
SVC
2912
Service Properties Trust
SVC
$1.09B
| $36.2K | ﹤0.01% |
3,937
-3,900
| -50% | -$39.2K |
|
2913
Cellectar Biosciences
CLRB
$20M
| $36.1K | ﹤0.01% |
+12,243
| New | +$45.2K |
|
2914
Stran & Co
SWAG
$37.8M
| $36.1K | ﹤0.01% |
21,734
+11,562
| +114% | +$22.6K |
|
2915
Battalion Oil
BATL
$28.2M
| $35.7K | ﹤0.01% |
31,627
+13,523
| +75% | +$15.5K |
|
2916
Spero Therapeutics
SPRO
$69.5M
| $35.4K | ﹤0.01% |
15,175
-18,626
| -55% | -$43.2K |
|
2917
Actinium Pharmaceuticals
ATNM
$27.2M
| $35.3K | ﹤0.01% |
25,976
+6,015
| +30% | +$8.78K |
|
2918
TOP Financial Group
TOP
$1.4B
| $35.1K | ﹤0.01% |
+35,128
| New | +$40.2K |
|
|
ASBP
2919
Aspire Biopharma
ASBP
$9.38M
| $35K | ﹤0.01% |
221
+198
| +861% | +$49.5K |
|
|
INTZ
2920
Intrusion
INTZ
$17.7M
| $34.9K | ﹤0.01% |
+30,390
| New | +$47.9K |
|
|
ITOC
2921
iTonic Holdings
ITOC
$4.42M
| $34.9K | ﹤0.01% |
82,835
+33,427
| +68% | +$19.9K |
|
|
YMT
2922
Yimutian Inc
YMT
$2.44M
| $34.8K | ﹤0.01% |
+1,470
| New | +$32.1K |
|
|
SOHO
2923
DELISTED
Sotherly Hotels
SOHO
| $34.8K | ﹤0.01% |
16,199
+983
| +6% | +$1.76K |
|
|
NIXX
2924
Nixxy Inc
NIXX
$20.2M
| $34.8K | ﹤0.01% |
36,252
+19,320
| +114% | +$25.9K |
|
|
ZEO
2925
Zeo Energy
ZEO
$18.6M
| $34.5K | ﹤0.01% |
31,696
+3,515
| +12% | +$4.82K |
|
Similar funds
HW
AAM
RWM
SAM
PP
VH
TSW
KIM
XTX Topco's Q4 2025 Portfolio in Review
As of Q4 2025, XTX Topco held 3,983 positions worth $3.81B, up 98% from $1.93B the previous quarter. Its ten largest holdings account for 5.5% of the portfolio.
XTX Topco deployed $1.94B of net new capital in Q4 2025, opening 1,493 new positions and adding to 1,108 existing holdings. Its largest new stake was T-Mobile US: 74,738 shares worth $15.2M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 14% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $8.34M trimmed.
- XTX Topco's largest Q4 2025 buy was T-Mobile US: 74,738 shares worth $15.2M.
- XTX Topco added most to Procter & Gamble in Q4 2025, an estimated $25.6M increase.
- XTX Topco's biggest Q4 2025 reduction was Bristol-Myers Squibb, cutting an estimated $8.34M.
- XTX Topco fully exited Johnson & Johnson in Q4 2025, selling an estimated $11.3M.
- XTX Topco's ten largest holdings make up 5.5% of its $3.81B portfolio in Q4 2025.
- XTX Topco opened 1,493 new positions and closed 727 in Q4 2025.
- XTX Topco's portfolio value rose 98% quarter-over-quarter to $3.81B.
Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.